Language: 简体中文 English


Wang Chen, Vice President and Academician, Chinese Academy of Engineering; President, Chinese Academy of Medical Sciences and Peking Union Medical College; Vice Chair, Global Alliance Against Chronic Respiratory Diseases. 

Dr. Wang has long been engaged in the clinical practice, research and teaching of respiratory medicine and has special expertise in pulmonary embolism, pulmonary hypertension, respiratory failure, pulmonary heart disease, chronic obstructive pulmonary diseases (COPD, Chronic Bronchitis Emphysema), new respiratory infectious diseases and tobacco epidemiology. He has contributed many important innovations, including the development of thrombolysis therapy and sequential mechanical ventilation, both of which have been added to international treatment guidelines. He oversees multiple national research projects and international programs.

Dr. Wang led the design and implementation of crucial measures for the prevention and control of COVID-19, including formulation of clinical guidelines, utilization of Fangcang shelter hospital, clinical trials to evaluate the effectiveness of Lopinavir-Ritonavir and Remdesivir in COVID-19 patients. He proposed a novel “Fangcang shelter hospital” approach in Wuhan, obviating the risk of within-household and community transmission and contributing to the successful COVID-19 control in China.

Dr. Wang has published more than 250 articles in authoritative international medical journals, such as the New England Journal of MedicineThe Lancet and Annals of Internal Medicine. He has been honored as the winner of the WHO’s Outstanding Contribution Award for Tobacco Control, the Ho Leung Ho Lee Foundation’s Scientific and Technological Progress Award, and the First Prize (once) and Second Prize (three times) of the National Science and Technology Progress Award.

As a former senior administrator of multiple medical institutions—including the Beijing Chao-Yang Hospital, Beijing Hospital and the China-Japan Friendship Hospital—Dr. Wang made major advances in subject development and hospital management. He also previously worked as the Deputy Director-General of the Department of Health Sciences, Technology and Education of the National Health Commission of P.R. China; in his time presiding over the Department, Dr. Wang  promoted medical education and research at the national level.

Richard Horton

Richard Horton is Editor-in-Chief of The Lancet.  He qualified in physiology and medicine with honours from the University of Birmingham in 1986. He joined The Lancet in 1990, moving to New York as North American Editor in 1993. In 2016, he chaired the Expert Group for the High-Level Commission on Health Employment and Economic Growth, convened by Presidents Hollande of France and Zuma of South Africa. 

From 2011 to 2015, he was co-chair of the UN's independent Expert Review Group on Information and Accountability for Women's and Children's Health. In 2011, he was elected a Foreign Associate of the US Institute of Medicine and, in 2015, he received the Friendship Award from the Government of China. 

In 2019 he was awarded the WHO Director-General’s Health Leaders Award for outstanding leadership in global health and the Roux Prize in recognition of innovation in the application of global health evidence.  He wrote Health Wars (2003) about contemporary issues in medicine and health.  He has a strong interest in global health and medicine’s contribution to our wider culture. He now works to develop the idea of planetary health – the health of human civilizations and the ecosystems on which they depend.


CAO Bin, MD., Vice President of China-Japan Friendship Hospital, Director of Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; Vice Director of National Center for Respiratory Medicine; Vice President of Institute of Respiratory Medicine, Chinese Academy of Medical Sciences. He is the associate editor of Clinical Respiratory Journal, editorial advisory board member of EBoiMedicine, and committee member of Antiviral Group (AVG) of International Society of Influenza and other respiratory virus Diseases (ISIRV). 

He has been honored with the title of National Outstanding Individual in the Fight against COVID-19 in 2020, Distinguished Respiratory Academic Contribution Award in 2018, National Award for Science and Technology Progress (Grand Prize) in 2017, Yangtze River Distinguished Professor of Ministry of Education in 2015 and Wu JiePing-Paul Janssen Medical-Pharmaceutical Award in 2014. 

As a senior expert in respiratory infections, his research mainly focuses on acute respiratory infections and emerging infectious diseases. He reported clinical characteristics of COVID-19 and risk factors for severe disease  during the period of assistance in Wuhan. He is also leading the antiviral clinical trials in China, including Remdesivir and lopinacir-ritonavir. He has published 188 original peer reviewed articles and reviews, among which 7 representative papers are published in Lancet or NEJM, 5 papers are listed as Highly Cited Paper in ESI, 10 papers are recommended by F1000Prime, and 16 papers are cited by domestic or foreign guidelines.

Gabriel LEUNG

Gabriel LEUNG is the fortieth Dean of Medicine (2013-), inaugural Helen and Francis Zimmern Professor in Population Health and holds the Chair of Public Health Medicine at the University of Hong Kong (HKU). He was the last Head of Community Medicine (2012-3) at the University as well as Hong Kong's first Under Secretary for Food and Health (2008-11) and fifth Director of the Chief Executive's Office (2011-2) in government.  

Leung is one of Asia’s leading epidemiologists and global health exponents, having authored more than 500 scholarly papers with an h-index of 69 (Scopus).  His research defined the epidemiology of three novel viral epidemics, namely SARS in 2003, influenza A(H7N9) in 2013 and most recently COVID-19.  He also led Hong Kong government’s efforts against pandemic A(H1N1) in 2009.  

He has been an official adviser to the Hong Kong SAR and Chinese Central People's Governments, as well as to numerous overseas jurisdictions and international agencies including the World Health Organisation.  He edited the Journal of Public Health (2007-14), was inaugural co-editor of Epidemics, associate editor of Health Policy and is founding deputy editor-in-chief of China CDC Weekly.  He currently serves on the editorial boards of seven journals, including the British Medical Journal.

Holger J. Schünemann

Holger J. Schünemann, M.D., M.Sc., Ph.D., FRCPC; Professor, Clinical Epidemiology and of Medicine, Departments of Health Research Methods, Evidence, and Impact and of Medicine;Director, WHO Collaborating Centre for Infectious Diseases, Research Methods and Recommendations;Director, Cochrane Canada and McMaster GRADE Centre.

Holger Schünemann is a tenured professor in the Departments of Health Research Methods, Evidence, and Impact and of Medicine at McMaster University. From 2009 to 2019, he completed his two terms as Chair of Clinical Epidemiology and Biostatistics at McMaster University, widely considered the birthplace of evidence-based health care. He trained in respiratory and exercise physiology and internal medicine at the Medical School of Hannover (MD in 1993 & Dr. med. in 1994) and lung biology, epidemiology, internal medicine and preventive medicine/public health at the University at Buffalo (UB), State of New York (M.Sc. Epidemiology in 1997; Ph.D. Epidemiology & Community Medicine in 2000). He was on faculty at UB and, from 2007 to 2009, interim Chair of Epidemiology at the National Cancer Institute in Rome, Italy. 

Since 2000, he helped reshaping of methodology for guideline development spanning clinical medicine to public health and contributed methodologically and practically to knowledge synthesis research, foremost through his co-leadership of the GRADE working group that he co-chairs. As author of over 700 publications (h-index 145/101 google scholar/web of science) he is among the 1000 most cited scientists historically. He has been advisor and chair of many guideline expert groups for WHO, the European Commission, ministries of health, other governmental organizations and professional societies. He is director of Cochrane Canada and the McMaster GRADE center. Maintaining an active internal medicine practice fulfills his passion for patient care and ensures his research is people-oriented.  

WANG Helena

Wang Helena is the Asia Executive Editor of The Lancet. She is also the fast track editor, writes editorials for The Lancet, and the ex-council member of COPE. She is responsible for China themed issue, The Lancet-CAMS Health Conference, The Lancet Commissions, The Wakley- Wu Lien Teh Prize and etc.  She participates in medical conferences domestically and globally, makes speeches in important academic conferences, and facilitates the academic collaboration between China and the rest of the world.

Jeffrey D. Sachs

Jeffrey D. Sachs is a University Professor and Director of the Center for Sustainable Development at Columbia University, where he directed the Earth Institute from 2002 until 2016. He is also Director of the UN Sustainable Development Solutions Network and a commissioner of the UN Broadband Commission for Development. He has been advisor to three United Nations Secretaries-General, and currently serves as an SDG Advocate under Secretary General António Guterres. He spent over twenty years as a professor at Harvard University, where he received his B.A., M.A., and Ph.D. degrees. He has authored numerous bestseller books. His most recent book is The Ages of Globalization: Geography, Technology, and Institutions (2020). Sachs was twice named as one of Time magazine’s 100 most influential world leaders and was ranked by The Economist among the top three most influential living economists. 

WANG Jianwei

Dr. Wang Jianwei is Professor in the Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC) in Bejing. He is currently the vice president of CAMS&PUMC. For the past 25 years, his research interest has been focused on the pathogenic mechanism and prevention of respiratory viral infectious diseases. Dr. Wang is the National Science Fund for Distinguished Young Scholars (2012), the leader of innovation team of Ministry of Education (2013), the first batch of scientific and technological innovation leading talents of national "ten thousand talents plan"(2013), the experts enjoying the special allowance of the State Council (2013), the young and middle-aged experts with outstanding contributions from the Ministry of Health (2013), the national level candidates for the million million talents project (2009), the national outstanding talents Scientific and technological workers (2016) and other honorary titles. 

He is also a member of the general team of the Major Science and Technology Major Project for prevention and control of major infectious diseases such as AIDS and viral hepatitis, and a member of the national key special expert group of "research and development of key technologies for biosafety".  Dr. Wang is an executive director of the Sixth Council of Chinese Preventive Medicine Association and a chairman of bioinformatics branch (to be appointed), vice chairman of medical virus branch of Chinese Medical Association, and an executive editor in chief of biosafety & health, an editorial board member of frontier in microbiology, etc. It has undertaken nearly 20 scientific research projects including the National 863 plan, 973 Plan, the Major Scientific and Technological Projects, and the National Natural Science Foundation of China. 

As a corresponding author, he has published about 110 SCI papers in LancetAm J Resp Med Crit Care, Cell Host & Microbe, PNAS, Nat commun, Microbiome and other journals. His papers have been cited for more than 18000 times (Research gate data), and won 7 science and technology awards at provincial and ministerial level and above.


Qiao Jie, is Academician of Chinese academy of engineering, Academician of American Academy of Arts and Sciences (IHM), Executive Vice Deputy Director of Peking University Health Science Center, President of Peking University Third Hospital.

Her reproductive research focus on the molecular mechanism of human gametogenesis and embryo development, infertility causes and clinical treatments, the protection and preservation of female fertility as well as developing new pre-implantation diagnosis methods. Qiao has led the team to achieve a number of technical and theoretical breakthroughs in the systematic study of human embryonic development and team made many landmark contributions to the development of reproductive medicine. During this pandemic, Jie Qiao, as the leader of Hubei medical aid team of Peking University, is responsible for critical and maternal care.

FENG Luzhao

Feng luzhao, Chinese Academy of Medical Sciences & Peking Union Medical College.Dr. Feng’s research interests include the epidemiology, disease burden, and vaccine policy of infectious diseases such as seasonal and avian influenza, RSV, COVID-19. He has published over 140 articles in international and Chinese journals, including The Lancet, Lancet Public Health, Bulletin of World Health Organization, etc. He was awarded the Provincial-level prize of science and technology of for 7 times. 

Roy M. Anderson

Sir Roy M. Anderson is Professor of Infectious Disease Epidemiology in the School of Public Health, Faculty of Medicine, Imperial College London and Director of the Centre for Neglected Tropical Disease Research. His recent appointments include Rector of Imperial College London and Chief Scientist at the Ministry of Defence, UK. His research interests are in interdisciplinary studies at the interface between medicine, biology, mathematics and computation.

He is the author of over 550 scientific articles and has sat on numerous government and international agency committees advising on public health and disease control including the World Health Organisation, Bill and Melinda Gates Foundation and UNAIDS. From 1991-2000 he was a Governor of the Wellcome Trust and for 10 years he was on the main board of GlaxoSmithKline up to May 2018. He is an Honorary Fellow of the Institute of Actuaries, the Royal College of Pathologist, the Royal Society of Agriculture and the Royal Statistical Society. He is also an honorary member of the Royal College of Physicians.

Sir Roy was elected Fellow of the Royal Society in 1986, a Founding Fellow of the Academy of Medical Sciences in 1998, a Foreign Associate Member of the National Academy of Medicine of at the US National Academy of Sciences in 1999 and a Foreign Member of the French Academy of Sciences in 2009. He was knighted in the 2006 Queen's Birthday Honours.'

CHEN Simiao

Dr. Chen Simiao is the Head of Research Unit for Health and Population Economics at Heidelberg Institute of Global Health at Heidelberg University in Germany, a Visiting Professor at Chinese Academy of Medical Sciences & Peking Union Medical College in China, and an Alexander von Humboldt Research Fellow. Her primary areas of research include population health, health economics, aging, health system, and health policy, mainly focusing on the public health emergency response policies, the interrelations between health status and economic growth, the impact of policies on health and economic development, as well as social determinants of health. She has published more than 30 articles in renowned journals such as the Lancet, JAMA, BMJ, Lancet Planetary Health, Science Translational Medicine, Health Affairs, and Social Science and Medicine. 

Simiao was also a consultant for the World Bank, Pan American Health Organization, the Chinese Academy of Engineering, and Population Council in Pakistan. She received her bachelor degree in industrial engineering from Tsinghua University, master degree in management science from Columbia University, and doctorate in population health economics from Harvard University.

Till Bärnighausen

Prof. Dr. Till Bärnighausen is the Director of the Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital of the University of Heidelberg. He is also the Alexander von Humboldt Professor at the University of Heidelberg, Faculty Fellow at the Harvard Center for Population and Development Studies, and Senior Faculty at one of the five Global Programmes of the British Wellcome Trust, the Africa Health Research Institute (AHRI) in South Africa. 

Prof. Bärnighausen’s research focuses on identifying, designing and testing novel interventions for population health and establishing the causal impact of interventions on population health, social and economic outcomes. In particular, he works on large-scale population-based experiments and quasi-experiments to reduce major global disease burdens in Africa, Asia and Europe – such as HIV, COVID-19, diabetes, hypertension, depression, and maternal and child health. His work has also contributed to our understanding of the major structural and behavioral drivers of population health, including aging, mobility, climate change, sexual risk behaviors, diet, exercise and drug use. 

Prof. Bärnighausen has published more than 500 peer-reviewed articles, including in Science, Science Translational Medicine, Nature Communications, PNAS, Lancet, Lancet Global Health, JAMA, JAMA Internal Medicine, PLOS Medicine, BMC Medicine, and BMJ. His publications have been cited >45,000 times (for an h-index of 84).

Winnie YIP

Dr. Winnie YIP is Professor of Global Health Policy and Economics at the Harvard School of Public Health. She is faculty director of the school-wide Harvard China Health Partnership that collaborates with a network of twelve academic and research institutions in China to conduct research that aims to improve affordable, effective and sustainable health care for the Chinese population, especially the rural population. She is also the Acting Director of the Fairbank Center for Chinese Studies at Harvard University for 2020-2021.

Dr. Yip holds a PhD in Economics from the Massachusetts Institute of Technology. Her research addresses the question of how to transform health care resources into effective services through health system interventions that integrate financing, provider payment incentives, organization, management and technology. In addition, she has studied and advised health care reforms in the wider Asia region, including Hong Kong, Taiwan, Thailand, Malaysia, Vietnam, and notably India. 

Dr. Yip is President of the International Health Economics Association and a member of Track II Dialogue on Healthcare of the National Committee on U.S.-China Relations, a commissioner for the Lancet Commission for Ageing in China and the Lancet Commission on Primary Health Care in China. She was a member of the five-person Technical Advisory Committee for the Healthy China: Deepening Health Reform in China report sponsored by the World Bank and the World Health Organization. She is the Senior Editor for Health Policy of Social Science and Medicine (Elsevier) and Health Systems & Reform (Francis&Taylor). She was Associate Editor of Health Economics (Wiley). 


Cun wei is a professor at the Institute of Medical Biology, Chinese Academy of Medical Sciences. He graduated from Peking Union Medical College with a PhD in 2006. He Invented the two-liquid phase purification technology for low-endotoxin bacterial capsular polysaccharides. Two vaccines based on the technology have entered phase III clinical trials。His lab is currently engaged in the research and development of hepatitis C virus and SARS-CoV-2 subunit vaccines.

Xu Wenbo

Xu Wenbo,Director, National Institute for Viral Disease Control and Prevention, China CDC. Fields of research: Strategy for the prevention and control of the infectious diseases including measles, rubella, poliomyelitis, hand food and mouth disease, pneumonia associated with adenovirus、SARS-CoV-2. He led a team that quickly identified the new type of adenovirus 55.

LIU Yuanli

Liu Yuanli, Councilor of the State Council's Councilors' Office, Professor and Dean, Peking Union Medical College School of Health Policy and Management. Since 1993, Dr. Liu has been closely involved in China's series of policy and strategic research studies addressing major reform and development issues.

ZHAI Zhenguo

Dr. ZHAI Zhenguo, board certified in Pulmonary and Critical Care medicine, now works in Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Clinical Research Center of Respiratory Diseases, Beijing, China.

Dr Zhai serves as the Secretary and Vise-director of Assembly of Pulmonary Embolism and Pulmonary Vascular Diseases in Chinese Thoracic Society. He also serves as a fellow of Pulmonary Vascular Research Institute (PVRI), a member of American College of Chest Physicians (ACCP). He is an author of numerous articles, textbook chapters and a contributor to teaching of acute venous thromboembolic disease and pulmonary hypertension.


As a core member, Dr Zhai has actively participated several clinical and translational studies and organized the Network System for pulmonary vascular diseases. The epidemiological data of pulmonary embolism in China and the baseline data of VTE prevention were obtained. Research interests are in management of venous thromboembolism, acute and longer-term management of pulmonary embolism and pulmonary hypertension. His team is committed to the National Program for Prevention and Management of Pulmonary Embolism and Deep Venous Thrombosis. He is clinically active as a teaching physician staffing fellows, residents, and medical students in Peking Union Medical College, Capital Medical University and Peking University. 


LIU Zhong

Dr. Zhong LIU graduated from Charité Medcal school,Homboldt-University,Berlin, Germany. Vice Director of Institute of Blood Transfusion in Chinese Academy of Medical Science (CAMS). Director of Heamo-vigilance Key Laboratory in Chinese Academic of Medical Science. Excultive Director of Blood Transfusion department in Peking Union Medical College (PUMC). Editor in Chief of Chinese Journal of Blood Transfusion. Chief expect of CAMS Initiative for innovative Medicine. Research interests: transfusion medicine, blood preservation and blood policy.

Key Dates

Online Conference Date:

(GMT)   8:00 - 12:00, Nov.24, 2020

(GMT) 10:00 - 14:00, Nov.25, 2020 

Online Registration Deadline:

November 25, 2020

Click for Registration